{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:34:33Z","timestamp":1783532073313,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ando.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T06:33:22Z","timestamp":1532500402000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Expert opinion on thyroid complications in immunotherapy"],"prefix":"10.1016","volume":"79","author":[{"given":"Frederic","family":"Illouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2018.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0065","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus placebo in resected stage III melanoma","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0075","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.007_bib0080","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/cen.13483","article-title":"Endocrinopathies with use of cancer immunotherapies","volume":"88","author":"Villa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.07.007_bib0090","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.07.007_bib0095","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.007_bib0100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0105","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ando.2018.07.007_bib0120","first-page":"2087525","article-title":"Treatment of ipilimumab induced graves\u2019 disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ando.2018.07.007_bib0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2018.07.007_bib0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.07.007_bib0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"10.1016\/j.ando.2018.07.007_bib0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/IOP.0000000000000033","article-title":"Ipilimumab-induced orbital inflammation resembling graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression","volume":"30","author":"Borodic","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ando.2018.07.007_bib0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000485742","article-title":"Severe inflammatory ophthalmopathy in a euthyroid patient during Nivolumab treatment","volume":"7","author":"Campredon","year":"2018","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2018.07.007_bib0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/bcr-2016-214603","article-title":"A rare case of thyroid storm","volume":"2016","author":"McMillen","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ando.2018.07.007_bib0155","first-page":"140092","article-title":"A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.ando.2018.07.007_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","author":"Khan","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2018.07.007_bib0185","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2018.07.007_bib0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ando.2018.07.007_bib0200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2018.07.007_bib0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 european thyroid association\/european group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2018.07.007_bib0210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1089\/thy.2012.0205","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association","volume":"22","author":"Garber","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2018.07.007_bib0215","doi-asserted-by":"crossref","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ando.2018.07.007_bib0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2018.07.007_bib0225","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2018.07.007_bib0230","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2018.07.007_bib0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2018.07.007_bib0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2018.07.007_bib0245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2018.07.007_bib0250","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ando.2018.07.007_bib0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ando.2018.07.007_bib0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines","volume":"28","author":"Hannen","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618311855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426618311855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:51:24Z","timestamp":1757717484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426618311855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0003426618311855"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.007","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert opinion on thyroid complications in immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.07.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}